Precision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform Study

NCT07729917 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

240

Enrollment

OTHER

Sponsor class

Conditions

Bile Duct Carcinoma
Cholangiocarcinoma

Interventions

DRUG: FGFR Inhibitor
DRUG: IDH1 mutation inhibitor
DRUG: KRAS mutation inhibitor
DRUG: NTRK mutation inhibitor
DRUG: BRAF V600E mutation inhibitor
DRUG: BRCA 1/2 mutation inhibitor
DRUG: HER2 target therapy
DRUG: Immune Checkpoint Inhibitors
DEVICE: Chemotherapy: GP/GEMOX

Sponsor

Zhejiang University